Avantax Advisory Services, Inc. Crispr Therapeutics Ag Transaction History
Avantax Advisory Services, Inc.
- $17.6 Billion
- Q2 2025
A detailed history of Avantax Advisory Services, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Avantax Advisory Services, Inc. holds 11,115 shares of CRSP stock, worth $812,173. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,115
Previous 10,651
4.36%
Holding current value
$812,173
Previous $362,000
49.17%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CRSP
# of Institutions
535Shares Held
68.7MCall Options Held
3.67MPut Options Held
2.25M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$744 Million4.09% of portfolio
-
Capital International Investors Los Angeles, CA5.59MShares$409 Million0.05% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.68MShares$269 Million0.11% of portfolio
-
State Street Corp Boston, MA3.27MShares$239 Million0.01% of portfolio
-
Ubs Group Ag2.84MShares$208 Million0.02% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $5.7B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....